17 03, 2023 Natural evolution of SARS-CoV-2 variants in K18-ACE2 mice gives rise to more virulent virus and variant alleles associated with treatment resistance Neal Evan Caminsky2023-03-17T09:32:07-04:00March 17, 2023|Funded Research Results, Pillar 3|
22 02, 2023 Comparison of COVID-19 vaccination rollout approaches across Canada: case studies of four diverse provinces Neal Evan Caminsky2023-02-24T14:36:10-05:00February 22, 2023|Funded Research Results, Pillar 8|
27 01, 2023 Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit stress granule formation Neal Evan Caminsky2023-01-27T15:58:35-05:00January 27, 2023|Funded Research Results, Pillar 3|
23 01, 2023 Third dose corrects waning immunity to SARS-CoV-2 mRNA vaccines in immunocompromised patients with immune-mediated inflammatory diseases Neal Evan Caminsky2023-01-23T10:01:17-05:00January 23, 2023|Funded Research Results, Pillar 4|
19 01, 2023 No time for complacency: The CoVaRR-Net Biobank is an essential element of laboratory preparedness for infectious disease outbreaks Neal Evan Caminsky2023-01-19T10:53:24-05:00January 19, 2023|Funded Research Results, CoVaRR-Net Biobank|
9 01, 2023 Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics Neal Evan Caminsky2023-07-17T15:42:02-04:00January 9, 2023|Funded Research Results, Pillar 10|
11 11, 2022 Evolution of naturally arising SARS-CoV-2 defective interfering particles Neal Evan Caminsky2022-11-22T18:36:16-05:00November 11, 2022|Funded Research Results, Pillar 5|
11 11, 2022 How do Social Factors Relate to the Number of COVID-19 Cases Among Indigenous Peoples Across Canadian Health Regions? Neal Evan Caminsky2022-11-15T09:12:47-05:00November 11, 2022|Funded Research Results, Pillar 7|
7 11, 2022 Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants Neal Evan Caminsky2022-11-22T18:37:06-05:00November 7, 2022|Funded Research Results, Pillar 3|
2 11, 2022 Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine but strong initial responses to a third dose Neal Evan Caminsky2022-11-15T09:12:42-05:00November 2, 2022|Funded Research Results, Pillar 1|
